Clinical Interventions in Aging
Open access peer-reviewed scientific and medical journals.
Dove Medical Press is now a member of the Open Access Initiative
An Author's Guide
A guide to help authors get their paper published.
Support Open Access and Dove Press
Promotional Article Monitoring - further details
Favored Author Program
Real benefits for authors, including fast-track processing of papers.
Six-month depot formulation of leuprorelin acetate in the treatment of prostate cancer
(6833) Total Article Views
Authors: Rajni Sethi, Nicholas Sanfilippo
Published Date June 2009
Volume 2009:4 Pages 259 - 267
Rajni Sethi, Nicholas Sanfilippo
Department of Radiation Oncology, New York University Langone Medical Center, New York, NY, USA
Abstract: Hormonal deprivation therapy is well established for the treatment of locally advanced and metastatic prostate cancer, as well as the adjuvant treatment of some patients with localized disease. Long-acting gonadotropin releasing hormone (GnRH) agonists have become a mainstay of androgen deprivation therapy, due to their efficacy, tolerability, and convenience of use. One-month, 3-month, and 4-month depot leuprorelin formulations are well established and widely used to this end. Recently, a 6-month depot leuprorelin has been approved for use in advanced and metastatic prostate cancer patients. With similar efficacy and side effect profiles to earlier formulations, 6-month depot leuprorelin is a convenient treatment option for these patients. This review will highlight the role of GnRH agonists in the treatment of prostate cancer with a focus on the clinical efficacy, pharmacology, and patient-focused outcomes of the newer 6-month 45 mg depot leuprorelin formulation in comparison to available shorter-acting products.
Keywords: prostate cancer, leuprorelin, hormonal deprivation therapy
Cannotea Citeulike Del.icio.us Facebook LinkedIn Twitter
Readers of this article also read:
- New eBook
Have a look at Dr Richard Walker's must read eBook on Amazon Kindle Why we age: Insight into the cause of growing old
- American Acne and Rosacea Society
The American Acne and Rosacea Society (AARS) is a 501(c)(6) non-profit organization dedicated to elevating the understanding and treatment of acne and rosacea.
- Have an opinion about one of our articles?
We encourage you to write a letter to the editor.
- Radio electric asymmetric brain stimulation in the treatment of behavioral and psychiatric symptoms in Alzheimer disease
- Eggshell membrane: A possible new natural therapeutic for joint and connective tissue disorders. Results from two open-label human clinical studies
- Comparison of two treatments for coxarthrosis: local hyperthermia versus radio electric asymmetrical brain stimulation
- The cognitive impact of anticholinergics: A clinical review